Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy.
J Pharmacol Exp Ther. 2010 May;333(2):465-77. doi: 10.1124/jpet.110.165605. Epub 2010 Feb 22.
Several lines of evidence suggest a biological role for peroxisome proliferator-activated receptor (PPAR)-beta/delta in the pathogenesis many diseases. The aim of the present study was to evaluate the contribution of PPAR-beta/delta in the secondary damage in experimental spinal cord injury (SCI) in mice. To this purpose, we used 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid (GW0742), a high-affinity PPAR-beta/delta agonist. Spinal cord trauma was induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5 to T8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, production of inflammatory mediators, tissue damage, and apoptosis. GW0742 treatment (0.3 mg kg(-1) i.p.) 1 and 6 h after the SCI significantly reduced 1) the degree of spinal cord inflammation and tissue injury (histological score), 2) neutrophil infiltration (myeloperoxidase activity), 3) nitrotyrosine formation, 4) proinflammatory cytokines expression, 5) nuclear factor-kappaB activation, 6) inducible nitric-oxide synthase expression, and 6) apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining, FasL, Bax, and Bcl-2 expression). Moreover, GW0742 significantly ameliorated the recovery of limb function (evaluated by motor recovery score). To elucidate whether the protective effects of GW0742 are related to activation of the PPAR-beta/delta receptor, we also investigated the effect of PPAR-beta/delta antagonist methyl 3-({[2-(methoxy)-4 phenyl]amino}sulfonyl)-2-thiophenecarboxylate (GSK0660) on the protective effects of GW0742. GSK0660 (1 mg/kg i.p. 30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect. Our results clearly demonstrate that GW0742 treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.
有几条证据表明过氧化物酶体增殖物激活受体 (PPAR)-β/δ 在许多疾病的发病机制中具有生物学作用。本研究的目的是评估 PPAR-β/δ 在实验性脊髓损伤 (SCI) 小鼠继发性损伤中的作用。为此,我们使用了 4-[[[2-[3-氟-4-(三氟甲基)苯基]-4-甲基-5-噻唑基]甲基]硫代]-2-甲基苯氧基]乙酸 (GW0742),一种高亲和力的 PPAR-β/δ 激动剂。通过在 T5 到 T8 椎板切除术中通过四个水平的硬脑膜应用血管夹(24 克的力)来诱导脊髓创伤。SCI 导致严重的创伤,表现为水肿、中性粒细胞浸润、炎症介质产生、组织损伤和细胞凋亡。GW0742 治疗(SCI 后 1 和 6 小时腹腔内 0.3mg/kg)显著降低 1)脊髓炎症和组织损伤的程度(组织学评分),2)中性粒细胞浸润(髓过氧化物酶活性),3)硝基酪氨酸形成,4)促炎细胞因子表达,5)核因子-κB 激活,6)诱导型一氧化氮合酶表达,6)细胞凋亡(末端脱氧核苷酸转移酶 dUTP 缺口末端标记染色、FasL、Bax 和 Bcl-2 表达)。此外,GW0742 还显著改善了肢体功能的恢复(通过运动恢复评分评估)。为了阐明 GW0742 的保护作用是否与 PPAR-β/δ 受体的激活有关,我们还研究了 PPAR-β/δ 拮抗剂甲基 3-({[2-(甲氧基)-4 苯基]氨基}磺酰基)-2-噻吩羧酸酯 (GSK0660) 对 GW0742 保护作用的影响。GSK0660(GW0742 治疗前 30 分钟腹腔内 1mg/kg)显著阻断了 PPAR-β/δ 激动剂的作用,从而消除了保护作用。我们的结果清楚地表明,GW0742 治疗可减少与脊髓创伤相关的炎症和组织损伤的发展。